Henry Schein delivered its strongest quarter in nearly four years, reporting Q4 2025 revenue of $3.44 billion — beating Wall Street's $3.28 billion consensus by 4.9% and marking the highest sales growth in 15 consecutive quarters. Adjusted EPS came in at $1.34, topping the $1.28 estimate by 4.7%. The dental distribution giant cited momentum across its global equipment, specialty products, and technology businesses as the primary growth drivers. Robert W. Baird responded by upgrading the stock to "Outperform" and raising its price target from $78 to $104, citing confidence in double-digit earnings growth potential starting in 2027.

The results are significant because Henry Schein's performance serves as a barometer for the broader dental economy. As the largest dental distributor globally, the company's sales trends reflect real-time demand from dental practices — for everything from consumables and PPE to digital imaging systems and CAD/CAM equipment. The 15-quarter sales growth high suggests that dental practices are spending again after a cautious 2024, particularly on technology upgrades that had been deferred during the post-pandemic normalization period. Full-year 2025 revenue came off a $13.2 billion base, and the company is projecting 3-5% top-line growth in 2026 with non-GAAP EPS guidance of $5.23 to $5.37.

For dental practices and DSOs, Schein's guidance signals a stabilizing supply chain and a competitive distribution market. The company's value creation initiatives — targeting $125 million in annual run-rate operating income improvements by year-end 2026 — suggest pricing discipline will remain tight, which benefits buyers. Equipment spending momentum also indicates that practices are investing in digital workflows, a trend that typically signals confidence in patient volume and revenue outlook. For DSOs evaluating technology rollouts across their portfolios, Schein's results validate that the digital upgrade cycle still has room to run.

Watch for Schein's Q1 2026 results to confirm whether the momentum is sustainable or whether the Q4 strength reflected year-end budget flushing. Key metrics to track include equipment sales growth (the highest-margin category), the pace of specialty product adoption, and any commentary on tariff impacts to imported dental supplies. Stanley Bergman's recent sale of 43,812 shares on March 5 also bears monitoring — insider selling after a strong quarter is not unusual, but it warrants attention given the stock's recent run.